Deals

Most transformations are predictable: A caterpillar will turn into a butterfly; a cell will be genetically altered should extraneous DNA enter its membrane. Predictable would…

Now that it has closed on its $63 billion acquisition of Allergan, AbbVie has significantly expanded its revenue base, which could help cushion the blow…

The turmoil in the stock market over the past month or so has sent leading healthcare indices reeling, casting a cloud over the financing that…

The OIS Index of ophthalmic stocks followed global stock markets into bear market territory in Q1, declining 21.2%, in line with the overall US stock…

The explosion of healthcare information technology has engendered a chaotic landscape of infinite terabytes of disparate but mutually relevant data segregated in infinite silos where…

Last week we heard firsthand at OIS@SECO’s second annual event just what it means to be innovative in the field of optometry. Leading off the…

Editor’s Note: The FDA just approved Allergan’s Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on…

Israel’s second name is “start-up nation,” and there are anywhere from 50-70 companies developing products for the eye care industry in Israel. From a monetary…

Media coverage of AbbVie’s (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in June was both bullish and bearish. In our initial coverage, we took a…